OS Therapies Inc. has released a corporate presentation highlighting its recent developments and pipeline progress. The company has acquired all listeria-based assets from Advaxis/Ayala, with over $300 million invested in the listeria platform to date. Its lead clinical program, OST-HER2, targets osteosarcoma with additional applications in breast cancer and other solid tumors. The total addressable market for these assets and follow-on applications is estimated at $258 billion. OST-HER2 has received orphan drug, fast track, and rare pediatric disease designations from the FDA, and the company is preparing for meetings with global regulatory agencies regarding submissions for human osteosarcoma. Accelerated approval is targeted for 2026, and a Priority Review Voucher could be issued upon approval, with recent comparable sales valued at $160 million. Other pipeline highlights include a next-generation tunable drug conjugate (OST-tADC) and ongoing clinical and preclinical programs in multiple cancer types. The estimated topline US revenue for OST-HER2 in osteosarcoma is projected to exceed $500 million, with the canine osteosarcoma market estimated at $150 million. You can access the full presentation through the link below.